Anthony Heaney, MD, PhD, Professor of Medicine, Department of Medicine, Co-Director, Pituitary Tumor and Neuroendocrine Program, Ronald Reagan UCLA Medical Center
Richard Auchus, MD, PhD, James A Shayman and Andrea S Kevrick Professor of Translational Medicine, Professor of Internal Medicine, Professor of Pharmacology, University of Michigan Medical School
Lisa Nachtigall, MD, Clinical Director, Neuroendocrine and Pituitary Tumor Center, Massachusetts General Hospital, Associate Professor of Medicine, Havard Medical School
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s peer reviewers.
DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
Anthony Heaney, MD, PhD: Novo Nordisk, Advisory Board, Speaker; Crinetics, Advisory Board; Recordati, Advisory Board, Speakers Bureau; Corcept, Speaker CASCADE Program; Lundbeck, Consultant
Richard Auchus, MD, PhD: Spruce Biosciences, Corcept, Neurocrine Biosciences, Neurocrine UK, LTD, Contracted Research Support and Consultant; Sparrow Pharmaceuticals, Consultant; Adrenas Therapeutics, Mineralys Pharmaceuticals, Contracted Research Support; Novo Nordisk, Quest Diagnostics, H Lundbeck A/S, Consultant; Crinetics Pharmaceuticals, Contracted Research Support; Xeris Pharmaceuticals, Consultant; Recordati, Contracted Research Support; OMass Therapeutics, Astellas Pharmaceuticals, Acerand Therapeutics, Blue Earth Diagnosis, LTD, Aspect Biosystems, United States Anti Doping Agency, National Football League, World Athletics, Consultant; CARES Foundation, APS1 Foundation, Seal Future foundation, Medical Advisory Board
Lisa Nachtigall, MD: Chiesi, Advisory Board and Research Funding (to institution); Crinetics, Avisory Board and Consultant; Recordati, Researching Funding (to institution)
The following Special Prgrams Committee member who planned and reviewed content for this activity reported no financial relationships:
Ismat Shafiq, MD
The Endocrine Society staff involved in the development of this CME activity reported no relevant financial relationships.
The Endocrine Society staff have reviewed all disclosures and resolved or managed all relevant identified conflicts of interest, as applicable.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by an educational grant from Corcept.